In this webinar for patients and caregivers, Elizabeth M. Jaffee, M.D., discusses the remarkable immunotherapy breakthroughs of 2018 and efforts to enable immunotherapy to benefit even more people with cancer in 2019. #CRIwebinar #immunotherapy

2018 was a big year for cancer immunotherapy. In addition to several approvals of checkpoint immunotherapies for new cancer types, combinations strategies involving these treatments were approved as first-line options in two cancer types and showed promise in clinical trials for several hard-to-treat cancers.

Important advances were also made with respect to immune-related biomarkers, cellular immunotherapies, and personalized vaccines.

In this webinar for patients and caregivers, Elizabeth M. Jaffee, M.D., covers these remarkable immunotherapy breakthroughs from the past year and discusses the field’s ongoing efforts to overcome the challenges ahead and enable immunotherapy to benefit even more people with cancer.

Elizabeth M. Jaffee, M.D., currently works at Johns Hopkins University in Baltimore, where she holds many prestigious positions, including serving as the deputy director of the Sidney Kimmel Comprehensive Cancer Center, the associate director of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, the Dana and Albert “Cubby” Broccoli professor of oncology, co-director of gastrointestinal cancer and diseases program, and co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care.

Outside of Johns Hopkins, Dr. Jaffee also currently serves as the chair of the National Cancer Advisory Board for the National Cancer Institute, the co-chair of the National Cancer Institute Blue Ribbon Panel for the National Cancer Moonshot Initiative, the leader of the Stand Up To Cancer-Lustgarten Foundation Pancreatic Cancer Dream Team, and the president of the American Association for Cancer Research, among other roles. Dr. Jaffee has received numerous awards in recognition of her contributions, including the AACR Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research in 2015 and the Johns Hopkins University Office of Women in Science and Medicine Vice Dean’s Award in 2012. She is a member of the Cancer Research Institute Scientific Advisory Council.

The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is hosted by our science writer, Arthur Brodsky, Ph.D. The 2019 series is made possible with generous support from Bristol-Myers Squibb and Cellectis.

Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series. [ Ссылка ]

The "Cancer Immunotherapy and You" webinar series is part of Cancer Research Institute's Answer to Cancer Patient Education Program. Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. [ Ссылка ]

свернуть